Payment overview · 2025
General Payments
$2,063.73
122 reported records · 18 companies
Healthcare provider profile · identity verified
Steven D Brown, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1811998008
Verified facts
What the public records show
CMS Open Payments records show Steven D Brown, D.O. received $2,063.73 in general payments during 2025 across 122 reported records.
PFIZER INC. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $407.52 | 19.8% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $400.07 | 19.4% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.56 | 13.0% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $225.11 | 10.9% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $181.94 | 8.8% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $88.81 | 4.3% | 5 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $61.85 | 3.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.42 | 2.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.92 | 2.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.75 | 2.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.85 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.02 | 2.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.85 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.73 | 1.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.43 | 1.6% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $29.13 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.34 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.43 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,063.73 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $345.16 | 19 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $334.43 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $218.69 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $216.74 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $211.02 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $171.35 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $148.88 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.89 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.04 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $98.04 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $88.81 | 5 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $61.85 | 4 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $61.85 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.42 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.71 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.71 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.02 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.02 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.17 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $8.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $8.37 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $7.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 162 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
162 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 558 | 144 |
| Alprazolam | Alprazolam | 534 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 156 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 124 |
| Gabapentin | Gabapentin | 414 | 93 |
| Tramadol Hcl | Tramadol Hcl | 408 | 75 |
| Lisinopril | Lisinopril | 375 | 112 |
| Omeprazole | Omeprazole | 330 | 100 |
| Clonazepam | Clonazepam | 310 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 92 |
| Lorazepam | Lorazepam | 248 | 43 |
| Eliquis | Apixaban | 236 | 47 |
| Metformin Hcl Er | Metformin Hcl | 216 | 70 |
| Furosemide | Furosemide | 207 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 51 |
| Famotidine | Famotidine | 185 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 48 |
| Montelukast Sodium | Montelukast Sodium | 176 | 56 |
| Trazodone Hcl | Trazodone Hcl | 175 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 27 |
| Atenolol | Atenolol | 169 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 162 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 36 |
| Ibuprofen | Ibuprofen | 156 | 40 |
| Losartan Potassium | Losartan Potassium | 152 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 54 |
| Jardiance | Empagliflozin | 145 | 28 |
| Sertraline Hcl | Sertraline Hcl | 145 | 54 |
| Metformin Hcl | Metformin Hcl | 143 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 36 |
| Methylprednisolone | Methylprednisolone | 130 | 107 |
| Simvastatin | Simvastatin | 128 | 37 |
| Carvedilol | Carvedilol | 122 | 29 |
| Prednisone | Prednisone | 120 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 39 |
| Topiramate | Topiramate | 119 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 30 |
| Allopurinol | Allopurinol | 108 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 40 |
| Synthroid | Levothyroxine Sodium | 96 | 25 |
| Potassium Chloride | Potassium Chloride | 89 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 25 |
| Ozempic | Semaglutide | 83 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 19 |
| Irbesartan | Irbesartan | 71 | 21 |
| Januvia | Sitagliptin Phosphate | 70 | 19 |
| Mirtazapine | Mirtazapine | 70 | 20 |
| Valsartan | Valsartan | 70 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Pregabalin | Pregabalin | 69 | 12 |
| Doxepin Hcl | Doxepin Hcl | 68 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 18 |
| Ezetimibe | Ezetimibe | 64 | 24 |
| Meloxicam | Meloxicam | 63 | 24 |
| Glimepiride | Glimepiride | 61 | 19 |
| Baclofen | Baclofen | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Celecoxib | Celecoxib | 58 | 19 |
| Finasteride | Finasteride | 57 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 21 |
| Ondansetron Odt | Ondansetron | 54 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | suppressed |
| Azithromycin | Azithromycin | 53 | 44 |
| Bumetanide | Bumetanide | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Spironolactone | Spironolactone | 51 | 18 |
| Linzess | Linaclotide | 50 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 37 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Azelastine Hcl | Azelastine Hcl | 46 | 14 |
| Cefuroxime | Cefuroxime Axetil | 46 | 39 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 20 |
| Repaglinide | Repaglinide | 46 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Colchicine | Colchicine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | 11 |
| Cephalexin | Cephalexin | 33 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Ibu | Ibuprofen | 33 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Fluconazole | Fluconazole | 28 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Mupirocin | Mupirocin | 17 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Pristiq | Desvenlafaxine Succinate | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,063.73 · 122 records | PFIZER INC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error